Species Reactivity Human/Mouse
Specificity Detects human and mouse FGF-23 in direct ELISAs and Western blots. Does not cross-react with recombinant human (rh) FGF acidic, rhFGF basic, rhFGF-3, -4, -5, -6, -7, -9, -10, -11, -12, -13, -16, -17, -18, -19, -20, -21, recombinant mouse (rm) FGF-8b, rmFGF-8c, or rmFGF-15.
Source Monoclonal Rat IgG2B Clone # 283511
Purification Protein A or G purified from hybridoma culture supernatant
Immunogen Mouse myeloma cell line NS0-derived recombinant mouse FGF-23 Tyr25-Val51 (Arg179Gln)
Accession # Q9EPC2
Formulation Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Recommended Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recombinant Human FGF-23 (Catalog # 2604-FG)</td>
<td>1 µg/mL</td>
</tr>
<tr>
<td>Recombinant Mouse FGF-23 (Catalog # 2629-FG)</td>
<td></td>
</tr>
</tbody>
</table>

Preparation and Storage

Reconstitution Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background

FGF-23 is a secreted protein primarily expressed in the brain and thymus. Mutations in FGF-23 produced by osteomalacia tumors are linked to autosomal dominant hypophosphatemic rickets and several bone structure disorders.